Challenging the effectiveness of green tea in primary and tertiary cancer prevention

被引:31
作者
Fujiki, Hirota [1 ]
Imai, Kazue [2 ]
Nakachi, Kei [2 ]
Shimizu, Masahito [3 ]
Moriwaki, Hisataka [3 ]
Suganuma, Masami [4 ]
机构
[1] Tokushima Bunri Univ, Fac Pharmaceut Sci, Tokushima 7708514, Japan
[2] Radiat Effects Res Fdn, Dept Radiobiol & Mol Epidemiol, Hiroshima 7320815, Japan
[3] Gifu Univ, Dept Med, Grad Sch Med, Gifu 5011194, Japan
[4] Saitama Canc Ctr, Res Inst Clin Oncol, Ina, Saitama 3620806, Japan
基金
日本学术振兴会;
关键词
Apoptosis; Delayed cancer onset; GADD153; Green tea tablet; Phase II prevention trial; Prospective cohort study; TNF-alpha; INDUCED COLON CARCINOGENESIS; (-)-EPIGALLOCATECHIN GALLATE; LUNG-CANCER; BREAST-CANCER; CELL-LINES; TNF-ALPHA; CONTROLLED-TRIAL; GENE-EXPRESSION; TUMOR PROMOTION; PHASE-I;
D O I
10.1007/s00432-012-1250-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Drinking green tea daily is part of Japanese culture, and various studies have revealed that green tea is a cancer preventive. We here review our progress in cancer prevention with green tea on 12 main topics, from basic to clinical level. Biochemical and biological studies of green tea catechins, a prospective cohort study, preclinical safety trials with tablets of green tea extract, double-blind randomized clinical phase II prevention trial for recurrence of colorectal adenomas, and synergistically enhanced inhibition by the combination of green tea catechins and anticancer drugs. All results were significant, including human studies with informed consent. Drinking 10 Japanese-size cups of green tea per day delayed the cancer onset of humans 7 years for females. For tertiary cancer prevention, consuming 10 cups of green tea per day fortified by green tea tablets, 50 %, significantly prevented the recurrence of colorectal adenomas. A minimum effective amount of green tea catechins for cancer prevention was found in humans. In addition, the combination of green tea catechins and anticancer drugs engendered a new cancer therapeutic strategy. The consumption of 10 Japanese-size cups of green tea per day is a significant factor in primary cancer prevention for the general population, and the preventive effect on recurrence of colorectal adenomas in patients is vital evidence in tertiary cancer prevention.
引用
收藏
页码:1259 / 1270
页数:12
相关论文
共 66 条
[1]   The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells [J].
Adachi, Seiji ;
Nagao, Tomokazu ;
Ingolfsson, Helgi I. ;
Maxfield, Frederick R. ;
Andersen, Olaf S. ;
Kopelovich, Levy ;
Weinstein, I. Bernard .
CANCER RESEARCH, 2007, 67 (13) :6493-6501
[2]   Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells [J].
Ahmad, N ;
Feyes, DK ;
Nieminen, AL ;
Agarwal, R ;
Mukhtar, H .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1997, 89 (24) :1881-1886
[3]  
[Anonymous], 1996, J Cell Biochem Suppl, V26, P236
[4]   Inflammation meets cancer, with NF-κB as the matchmaker [J].
Ben-Neriah, Yinon ;
Karin, Michael .
NATURE IMMUNOLOGY, 2011, 12 (08) :715-723
[5]   Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study [J].
Bettuzzi, S ;
Brausi, M ;
Rizzi, F ;
Castagnetti, G ;
Peracchia, G ;
Corti, A .
CANCER RESEARCH, 2006, 66 (02) :1234-1240
[6]  
Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO
[7]  
2-E
[8]  
Conney AH, 1992, INHIBITORY EFFECT OR, P361
[9]  
ELDEIRY WS, 1994, CANCER RES, V54, P1169
[10]   Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].
Fisher, B ;
Costantino, JP ;
Wickerham, DL ;
Redmond, CK ;
Kavanah, M ;
Cronin, WM ;
Vogel, V ;
Robidoux, A ;
Dimitrov, N ;
Atkins, J ;
Daly, M ;
Wieand, S ;
Tan-Chiu, E ;
Ford, L ;
Wolmark, N .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388